Subject(s)
Colorectal Neoplasms/prevention & control , Mass Screening/economics , Adult , Blue Cross Blue Shield Insurance Plans/economics , Colonoscopy/economics , Diagnosis-Related Groups , Female , Humans , Male , Mass Screening/methods , Middle Aged , Occult Blood , Sigmoidoscopy/economics , United StatesSubject(s)
Peptic Ulcer/history , History, 19th Century , History, 20th Century , Humans , Peptic Ulcer/therapy , United StatesSubject(s)
Cholangiopancreatography, Endoscopic Retrograde/statistics & numerical data , Health Services Misuse , Health Services , Cholangiopancreatography, Endoscopic Retrograde/adverse effects , Cholangiopancreatography, Endoscopic Retrograde/economics , Cost-Benefit Analysis , Health Services/economics , Health Services Misuse/economics , Humans , RiskSubject(s)
Hepatitis/etiology , Virus Diseases/complications , Acute Disease , Adolescent , Adult , Age Factors , Humans , Infant , Infant, Newborn , SyndromeSubject(s)
Cost-Benefit Analysis , Mass Screening/economics , Humans , Preventive Medicine/economics , Risk , United StatesABSTRACT
Cimetidine, a potent H2-receptor antagonist, has been introduced for the treatment of various conditions associated with acid peptic digestion in the gastrointestinal tract. Preliminary results are encouraging. Adverse reactions do not appear to be substantial; however, the effect of long-term use has yet to be ascertained.
Subject(s)
Gastric Juice/metabolism , Guanidines/pharmacology , Histamine H2 Antagonists/pharmacology , Imidazoles/pharmacology , Peptic Ulcer/drug therapy , Drug Evaluation , Gastric Mucosa/drug effects , Gastrointestinal Hemorrhage/drug therapy , Guanidines/adverse effects , Guanidines/therapeutic use , Histamine H2 Antagonists/adverse effects , Histamine H2 Antagonists/therapeutic use , Humans , Imidazoles/adverse effects , Imidazoles/therapeutic use , Secretory Rate/drug effectsABSTRACT
The introduction of dinoprost tromethamine (Prostin F2 Alpha) as an abortifacient in the second trimester of pregnancy represents the first clinical use of a prostaglandin. Various synthetic analogues of the naturally occurring derivatives are being employed investigationally in the treatment of peptic ulcer, hypertension, asthma, and hypercalcemia. In the United States, dinoprost tromethamine is primarily administered intra-amniotically. Despite the fact that a substantial number of patients experience allergic reactions, hypertension, bronchospasm, nausea, vomiting, cramps, and diarrhea, the efficacy and relative safety of dinoprost tromethamine establish it as superior to intra-amniotic instillation of hypertonic saline. Cervical laceration, laceration or rupture of the lower uterine segment, retention of the placenta, and hemorrhage in part reflect the intensity of uterine contraction induced by dinoprost. Experience in administration improves the therapeutic response and diminishes adverse reactions.